Citation 1:
    Title: Lilly Reports Q2 2024 Financial Results, Raises Full-Year Revenue Guidance by $3 Billion | Eli Lilly and Company
    URL: https://investor.lilly.com/news-releases/news-release-details/lilly-reports-q2-2024-financial-results-raises-full-year-revenue#:~:text=Second,and
    Location: chars 297–466

Citation 2:
    Title: Lilly reports first-quarter 2025 financial results and highlights pipeline momentum | Eli Lilly and Company
    URL: https://lilly.gcs-web.com/news-releases/news-release-details/lilly-reports-first-quarter-2025-financial-results-and#:~:text=,0%20billion
    Location: chars 634–793

Citation 3:
    Title: Lilly reports full Q4 2024 financial results and provides 2025 guidance | Eli Lilly and Company
    URL: https://investor.lilly.com/news-releases/news-release-details/lilly-reports-full-q4-2024-financial-results-and-provides-2025#:~:text=2025%20Financial%20Guidance%20The%20company,as%20Zepbound%2C%20Mounjaro%2C%20Jaypirca%2C%20Ebglyss
    Location: chars 950–1205

Citation 4:
    Title: Lilly reports first-quarter 2025 financial results and highlights pipeline momentum | Eli Lilly and Company
    URL: https://lilly.gcs-web.com/news-releases/news-release-details/lilly-reports-first-quarter-2025-financial-results-and#:~:text=obesity%20and%20diabetes%20Phase%203,0%20billion
    Location: chars 1206–1401

Citation 5:
    Title: Lilly Reports Q2 2024 Financial Results, Raises Full-Year Revenue Guidance by $3 Billion | Eli Lilly and Company
    URL: https://investor.lilly.com/news-releases/news-release-details/lilly-reports-q2-2024-financial-results-raises-full-year-revenue#:~:text=Strong%20performance%20by%20the%20company%27s,vials%20in%20the%20coming%20weeks
    Location: chars 1645–1883

Citation 6:
    Title: Lilly Reports Q2 2024 Financial Results, Raises Full-Year Revenue Guidance by $3 Billion | Eli Lilly and Company
    URL: https://investor.lilly.com/news-releases/news-release-details/lilly-reports-q2-2024-financial-results-raises-full-year-revenue#:~:text=Higher%20realized%20prices%20were%20primarily,offset%20by%20lower%20Trulicity%20sales
    Location: chars 1966–2210

Citation 7:
    Title: Lilly Reports Q2 2024 Financial Results, Raises Full-Year Revenue Guidance by $3 Billion | Eli Lilly and Company
    URL: https://investor.lilly.com/news-releases/news-release-details/lilly-reports-q2-2024-financial-results-raises-full-year-revenue#:~:text=Strong%20performance%20by%20the%20company%27s,vials%20in%20the%20coming%20weeks
    Location: chars 2356–2594

Citation 8:
    Title: Lilly reports first-quarter 2025 financial results and highlights pipeline momentum | Eli Lilly and Company
    URL: https://lilly.gcs-web.com/news-releases/news-release-details/lilly-reports-first-quarter-2025-financial-results-and#:~:text=In%20Q1%202025%2C%20research%20and,stage%20portfolio
    Location: chars 2820–3019

Citation 9:
    Title: Lilly Reports Q2 2024 Financial Results, Raises Full-Year Revenue Guidance by $3 Billion | Eli Lilly and Company
    URL: https://investor.lilly.com/news-releases/news-release-details/lilly-reports-q2-2024-financial-results-raises-full-year-revenue#:~:text=In%20Q2%202024%2C%20the%20company,1%20million%20in%20Q2%202023
    Location: chars 3207–3428

Citation 10:
    Title: Lilly Reports Q2 2024 Financial Results, Raises Full-Year Revenue Guidance by $3 Billion | Eli Lilly and Company
    URL: https://investor.lilly.com/news-releases/news-release-details/lilly-reports-q2-2024-financial-results-raises-full-year-revenue#:~:text=higher%20net%20interest%20expenses
    Location: chars 3935–4128

Citation 11:
    Title: Lilly Reports Q2 2024 Financial Results, Raises Full-Year Revenue Guidance by $3 Billion | Eli Lilly and Company
    URL: https://investor.lilly.com/news-releases/news-release-details/lilly-reports-q2-2024-financial-results-raises-full-year-revenue#:~:text=rate%20reflects%20the%20impact%20of,sale%20of%20rights%20for%20Baqsimi
    Location: chars 4321–4550

Citation 12:
    Title: Lilly Reports Q2 2024 Financial Results, Raises Full-Year Revenue Guidance by $3 Billion | Eli Lilly and Company
    URL: https://investor.lilly.com/news-releases/news-release-details/lilly-reports-q2-2024-financial-results-raises-full-year-revenue#:~:text=rate%20reflects%20the%20impact%20of,sale%20of%20rights%20for%20Baqsimi
    Location: chars 4660–4889

Citation 13:
    Title: Lilly Reports Q2 2024 Financial Results, Raises Full-Year Revenue Guidance by $3 Billion | Eli Lilly and Company
    URL: https://investor.lilly.com/news-releases/news-release-details/lilly-reports-q2-2024-financial-results-raises-full-year-revenue#:~:text=,informing%20the%20public%20about%20potentially
    Location: chars 5465–5671

Citation 14:
    Title: Lilly Reports Second-Quarter 2023 Financial Results, Highlights Accelerating Revenue Growth and Key Pipeline Advancements | Eli Lilly and Company
    URL: https://investor.lilly.com/news-releases/news-release-details/lilly-reports-second-quarter-2023-financial-results-highlights/#:~:text=of%20mirikizumab%20in%20the%20EU,09%20of%20acquired%20IPR%26D%20charges
    Location: chars 5765–5994

